SAN FRANCISCO--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. announced today that Julia P. Gregory, president and chief executive officer, will present an overview of the company, discuss the progress of FivePrime's lead clinical program, FP-1039, for oncology, its preclinical pipeline and recent announcement of a milestone achievement under the Centocor Research & Development, Inc. collaboration.
